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Combined Pharmacotherapy and Psychotherapy
in the Treatment of Mild to Moderate
Major Depression?
Treatment guidelines for major depressive disorders
suggest that combined treatment of pharmacotherapy
and psychotherapy may be helpful in the acute phase of
severe major depression.1 However, combined treat-
ment is not strongly recommended in mild to moder-
ate depression. In these cases, either pharmaco-
therapy or psychotherapy can be used, depending on the
preference of the patient, the treatment history, and
other clinical factors. However, is this recommendation
still supported by the current state of knowledge? In this
Viewpoint, I will discuss recent evidence suggesting that
combined treatment could be a first-line treatment in the
acute phase of mild to moderate depressive disorders
and whether this evidence is strong enough to recon-
sider the recommendations in treatment guidelines.
Evidence in Favor of Combined Treatment
The first piece of evidence in favor of combined treat-
ment in mild to moderate depression is straightfor-
ward. Combined treatment is more effective than either
pharmacotherapy or psychotherapy alone. Several doz-
ens of well-designed trials and meta-analyses have
clearly shown that combined treatment is superior, and
that is not only the case in studies of patients with se-
vere depression but also in studies of patients with mild
to moderate depression.2
Second, both pharmacotherapy and psycho-
therapy probably have the most robust effects on se-
vere depression and much smaller effects on mild to
moderate depression. For pharmacotherapy, it was first
suggested several years ago that effect sizes in mild to
moderate depression are not clinically relevant.3 There
are no validated methods available for establishing the
clinical relevance of outcomes of treatments, so rel-
evance for pharmacotherapy cannot be defined using a
statistical outcome such as an effect size. However, re-
gardless of whether treatment is clinically relevant or not,
the evidence that the effects of pharmacotherapy de-
crease with decreasing severity is quite strong.
The evidence that psychotherapy is more effective
for patients with severe depression and less so for pa-
tients with mild to moderate depression is less well es-
tablished, but the evidence supporting this is increas-
ing. It has long been thought that psychotherapy should
never be used for patients with severe depression. This
belief is based, in part, on the findings of the Treatment
of Depression Collaborative Research Program,4 in which
cognitive behavior therapy did not differ from placebo
for more severely depressed patients, whereas antide-
pressant medications did. These findings suggested that
pharmacotherapy was effective for severe depression
but that psychotherapy was not and should therefore
only be used for mild to moderate depression.
In the same study,4 however, interpersonal psycho-
therapy was examined, and it was found that interper-
sonal psychotherapy did differ from placebo for patients
with more severe depression, suggesting that psycho-
logical treatment can be efficacious in this population.
Furthermore, meta-analytic studies have shown that it
is also plausible that psychotherapy may be more
effective for patients with severe depression and less
effective for patients with mild to moderate depres-
sion, compared with controls.5 In addition, meta-
analyses of studies in which psychotherapy and phar-
macotherapy are directly compared with each other
have found that the 2 are equally effective, regardless
of baseline severity. Therefore, if pharmacotherapy is
less effective against mild to moderate depression,
and if psychotherapy and pharmacotherapy are
equally effective against mild to moderate depression,
then psychotherapy must also be less effective against
mild to moderate depression.
Therefore, if it is indeed true that both work best for
patients with severe depression but less well for pa-
tients with mild to moderate depression, should this not
be an argument for the use of combined pharmaco-
therapy and psychotherapy in the treatment of mild to
moderate depression? Combined treatment is more ef-
fective than either treatment alone, regardless of base-
line severity. And it is well known that many patients do
not respond at all or do not respond sufficiently to acute-
phase treatment, and that the majority have a relapse
within a couple of years after successful treatment. Ag-
gressive treatment with the most effective interven-
tions that are available may be the best option to im-
prove outcome in the short and long term.
There is another argument as to why combined
treatment may be the best treatment option in the
acute phase of mild to moderate depression. In a
recent meta-analysis,2 we examined 11 trials in depres-
sion and anxiety disorders in which combined treat-
ment, pharmacotherapy only, psychotherapy only, and
placebo conditions were examined. This meta-analysis2
showed again that the effects of psychotherapy and
those of pharmacotherapy vs the effects of placebo
were comparable. However, this study2 also showed
that the effects of combined treatment compared with
the effects of placebo were twice as large as those of
psychotherapy or pharmacotherapy only. This suggests
that the effects of these 2 treatments may be indepen-
dent of each other and that the effect of combined
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alone. Of course, this finding has to be considered with caution
because of the confidence intervals around the effect sizes and the
differences between the included studies. Functional imaging stud-
ies on depression indicate that pharmacotherapy and cognitive
behavior therapy both affect the orbitofrontal cortex bilaterally and
the left medial cortex but had differential effects on the cingulate
cortex and the caudate in responders.6 These complementary
effects of cognitive behavior therapy and pharmacotherapy sup-
port the notion that combined treatments may be more effective
and that there is no “cannibalization” of the effects of each of the
treatments. Over the past decade, an increasing proportion of
patients with mental disorders received psychotropic medication
without psychotherapy,7 and about 75% of the patients prefer
psychotherapy.8 It can be expected that many patients will prefer
combined treatment, when offered the possibility.
Arguments Against Combined Treatment
Are there arguments against combined pharmacotherapy and psy-
chotherapy in the treatment of mild to moderate depression? Yes,
there are. All treatments have advantages and disadvantages, in-
cluding a risk of adverse events, side effects of medications and psy-
chotherapy, and further deterioration during treatment. We do not
have sufficient knowledge about treatments yet to predict which
treatment works best for which patient. And whether or not com-
bined treatment should be given to patients with mild to moderate
depression should not only depend on the effects found in random-
ized trials but also on side effects, patient preferences, costs of treat-
ment, possible negative effects, comorbid conditions, and other clini-
cal circumstances, such as history of depression or history of
treatment. Current treatment guidelines do allow us to take such as-
pects into account.
Should Combined Treatment Be Recommended?
So, should combined psychotherapy or pharmacotherapy be rec-
ommended in the treatment of mild to moderate depression? The
evidence shows that combined treatment is significantly more ef-
fective than either treatment alone, that they are both not very ef-
fective when applied alone but are effective when combined, and
that the effects may be largely independent of each other. And cur-
rently the majority of patients receive pharmacotherapy, while they
would prefer psychotherapy. It is the physician and the patient who
should decide which treatment should be given to the patient, and
many factors play a role in this process. However, there is no doubt
that current evidence suggests that combined treatment could be
a valuable treatment alternative for patients with mild to moderate
depression.
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